N-[(4R)-4-[(3R,7R,9S,10S,12S,14S,17R)-3,7,12-tris(3-aminopropoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentyl]hexadecan-1-amine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: N-[(4R)-4-[(3R,7R,9S,10S,12S,14S,17R)-3,7,12-tris(3-aminopropoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentyl]hexadecan-1-amine
• 化学式: C₄₉H₉₆N₄O₃
• 分子量: 789.3
• InChiKey: LVXOMFMVNUAJBN-AKOXZZKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.6
• 重原子数：
  56
• 可旋转键数：
  32
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• US20140271761A1
  申请人：——

  公开号：US20140271761A1

  公开（公告）日：2014-09-18
• NOVEL ENDOTRACHEAL TUBE FOR THE REDUCTION OF INTUBATION-RELATED COMPLICATION IN NEONATES AND BABIES
  申请人：Brigham Young University

  公开号：US20170080128A1

  公开（公告）日：2017-03-23

  This disclosure relates to medical devices incorporating one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the medical devices to provide effective antimicrobial, anti-inflammatory, and/or tissue-healing properties. A medical device includes a component formed from a polymeric material. One or more CSA compounds are mixed with the polymeric material so that the one or more CSA compounds are incorporated into the structure of the medical device as formed from the polymeric material. A medical device can additionally or alternatively include a lubricious coating containing one or more CSA compounds.
• CATIONIC STEROIDAL ANTIMICROBIAL COMPOSITIONS FOR THE TREATMENT OF DERMAL TISSUE
  申请人：Savage Paul B.

  公开号：US20170258963A1

  公开（公告）日：2017-09-14

  This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.